Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The specific aims of the study are:
Primary: To determine the presence and regional distribution of microglial activation, as
assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET,
in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive
Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls
Secondary:
1. To assess the relationship between microglial activation and clinical variables
including disease severity and comorbidities (such as pain, fatigue and/or depression),
as well as clinical MRI findings (such as lesions and atrophy)
2. A pilot substudy aims to establish the non-inferiority of [F-18]PBR06 as compared with
Carbon-11 [C-11] labeled "Peripheral Benzodiazepine Receptor 28" (PBR28) PET in patients
with RRMS.
Hypothesis: The working hypothesis is that there is microglial activation in multiple
sclerosis and Alzheimer's disease as compared to healthy controls and that the pattern/
regional distribution of microglial activation is different in Multiple Sclerosis (MS) versus
AD and correlates with disease severity and comorbidities.
In addition, the investigators hypothesize that [F-18]PBR06-PET scans will be at least as
good as [C-11]PBR28-PET scans, the current gold standard.